Eleven Hong Kong Groups Unveil First-Ever Biotech Five-Year Plan to Drive Industry Growth

Summary

Key Points

• The proposal, titled "Hong Kong's First Five-Year Plan for Biotech Industry Development Policy Recommendations," was jointly issued by eleven groups including the Hong Kong Association of Bio-Health Innovation (HKBMIA), China State Construction International Medical Management Academy, the Democratic Alliance for the Betterment of Hong Kong, and the Greater Bay Area Entrepreneurs Alliance 1.
• The initiative responds to the national 15th Five-Year Plan's inclusion of biomedicine as an emerging pillar industry, identifying this as a critical window for Hong Kong to transition from "research advantage" to "industrial advantage" 1.
• Three strategic infrastructure projects form the core: establishing CMPR as an institutional cornerstone to develop "first-tier approval" capabilities targeting Southeast Asia and Belt and Road markets; developing Ngau Tam Mei, a third medical school, and teaching hospitals into an integrated medical-industry-academia research cluster; and leveraging public-private partnerships, industry funds, and clinical trial platforms 1.
• Key challenges identified include insufficient pilot-scale and GMP manufacturing facilities, non-platformized clinical trial recruitment, shortage of patient capital, lack of fixed translation collaboration mechanisms between hospitals, universities, enterprises, and regulators, and the need for the Northern Metropolis to shift from land planning to industrial operations 1.
• HKBMIA President Lo Yuk-lam stated that CMPR's value lies not only in shortening approval times but in building Hong Kong's credibility as an international medical product regulatory node, with the goal of becoming a Southeast Asia and Belt and Road drug regulatory hub within five years and an international authority comparable to the US FDA or European EMA within ten years 1.

Why It Matters